Samsung Bioepis latest report sees US biosimilar market evolving

South Korea’s Samsung Bioepis has released its Third Quarter 2024 Biosimilar Market Report, which includes the latest Average Sales Price (ASP) information of all biosimilars and reference products available in the US market.

The latest report is the sixth-edition of the Samsung Bioepis’ Quarterly Biosimilar Market Report including updates of biosimilar approval statuses, the definition of interchangeability in biosimilars and its exclusivity as well as a successful case of adalimumab biosimilar adoption through an interview with a pharmacy benefit manager (PBM) at Scripius.

“The US biosimilar market is continually evolving and the need to monitor change on a routine basis has become critical to stakeholder evaluations. Our report investigates the market share and price trends for each molecule, allowing readers to access and compare current market dynamics on a timely basis,” said Thomas Newcomer, vice president, head of market access, US, at Samsung Bioepis, adding: “The biosimilar market is no longer simple. However, as always, we strive to deliver quick and organized information to the US healthcare market.